XML 29 R16.htm IDEA: XBRL DOCUMENT v3.24.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2024
shares
Ben Dake  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

On July 8, 2024, Ben Dake, our former President, terminated a trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c) (the “Dake 10b5-1 Plan”). The Dake 10b5-1 Plan was entered into on November 16, 2023, and commenced on March 18, 2024, with a termination date of the earlier of December 31, 2024, or the date all shares under the plan were sold. The aggregate number of securities sold under the Dake 10b5-1 Plan was 72,696.
Name Ben Dake
Title President
Rule 10b5-1 Arrangement Terminated true
Termination Date July 8, 2024
Aggregate Available 72,696
Hunter Gillies  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

On July 10, 2024, Hunter Gillies, our former Chief Medical Officer, terminated a trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c) (the “Gillies 10b5-1 Plan”). The Gillies 10b5-1 Plan was entered into on January 19, 2023, and commenced on April 19, 2023, with a termination date of the earlier of July 17, 2024, or the date all shares under the plan were sold. The aggregate number of securities sold under the Gillies 10b5-1 Plan was 68,255.
Name Hunter Gillies
Title Chief Medical Officer
Rule 10b5-1 Arrangement Terminated true
Termination Date July 10, 2024
Aggregate Available 68,255
George Eldridge  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

On September 30, 2024, George Eldridge, our Chief Financial Officer, terminated a trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c) (the “Eldridge 10b5-1 Plan”). The Eldridge 10b5-1 Plan was entered into on March 17, 2023, and commenced on October 10, 2023, with a termination date of the earlier of September 30, 2024, or the date all shares under the plan were sold. The aggregate number of securities sold under the Eldridge 10b5-1 Plan was 64,995.
Name George Eldridge
Title Chief Financial Officer
Rule 10b5-1 Arrangement Terminated true
Termination Date September 30, 2024
Aggregate Available 64,995